GlassScriptPhysician profile
Paul C Krisa
NPI 1588608525
$6,058.69
in general payments reported to CMS, 2019-2025
48 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $775 · 2021: $1,148 · 2022: $1,138 · 2023: $1,480 · 2024: $372 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.34 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.93 | 2020-2025 | |
| Novo Nordisk INC | $530.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $432.03 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $417.82 | 2019-2024 | Farxiga, Airsupra, Lokelma |
| Amarin Pharma, INC. | $298.79 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $297.46 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $286.43 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $266.46 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $247.51 | 2019-2024 | Livalo |
| Astellas Pharma US INC | $226.75 | 2019-2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $193.04 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $191.68 | 2019-2024 | |
| Allergan, INC. | $169.68 | 2019-2020 | |
| Exact Sciences Corporation | $163.57 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $146.51 | 2020-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Krisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.